Study With Improved Solubility Pazopanib

Proof of Principle and Pharmacological Phase 0 Study With Improved Solubility Pazopanib

The pharmacokinetics of a new formulation with Pazopanib will be studied. This will be done in a patient cohort of n = 12.

Inclusion Criteria:

• Locally advanced or metastatic cancer;
• Able and willing to give written consent;
• WHO performance status of 0, 1 or 2;
• Able and willing to undergo blood sampling for PK analysis;
• Minimal acceptable safety laboratory values;
• Negative pregnancy test for female patients with childbearing potential;
• Able and willing to swallow oral medication.

Exclusion Criteria:

• Any treatment with investigational drugs within 30 days prior to receiving the investigational treatment;
• Any treatment with CYP3A4, BCRP or PGP interfering drugs;
• Patients who received treatment with Votrient(R) kess than 1 week ago;
• Woman who are pregnant or breast feeding;
• Patients suffering from any known condition that may influence the dissolution or absorption of Pazopanib.